Market research reports, consulting: Global Market Insights Inc.
We use cookies to enhance user experience. (Privacy Policy)

Cell Therapy Clinical Trial Services Market Analysis

Report ID: GMI9333
   |
Published Date: May 2024
 | 
Report Format: PDF

Download free sample

Cell Therapy Clinical Trial Services Market Analysis

Cell Therapy Clinical Trial Services Market, By Service, 2021 – 2032 (USD Billion)

Based on the service, the global market is classified into clinical trial design and planning, supply & logistics services, regulatory affairs & compliance, data management & biostatics, site management & monitoring, and other services. The regulatory affairs & compliance segment dominated the market with revenue of USD 662.4 million in 2023.

 

  • Regulatory compliance is essential to demonstrate the safety and efficacy of these therapies in clinical trials. Robust regulatory affairs practices help ensure that appropriate safety measures are implemented and followed throughout the development process.

     

  • Moreover, regulatory affairs professionals play a crucial role in identifying and mitigating various risks such as related to product variability, patient safety, and ethical considerations, through comprehensive risk management strategies. By ensuring compliance with regulatory requirements, companies can minimize risks associated with non-compliance and avoid delays in the development process. Such aforementioned factor is expected to spur the segmental growth.

 

Cell Therapy Clinical Trial Services Market, By Phase (2023)

Based on the phase, the global cell therapy clinical trial services market is classified into phase I, phase II, phase III, and phase IV. The phase II segment dominated the market with market share of 35.2% in 2023.

 

  • Phase II trials typically involve larger patient populations than Phase I trials, requiring efficient patient recruitment and retention strategies. Advances in patient engagement, site selection, and recruitment technologies contribute to the successful execution of Phase II trials.

     

  • Moreover, promising results from Phase I clinical trials demonstrating the safety and preliminary efficacy of a cell therapy, often lead to the initiation of Phase II trials. Therefore, sponsors are encouraged to advance promising candidates into Phase II to further evaluate their therapeutic potential. Thus, usage of trial services in phase II will augment the segmental growth.

     

Based on the indication, the global cell therapy clinical trial services market is classified into oncology, hematology, neurology, cardiovascular diseases, musculoskeletal disorders, and other indications. The oncology segment is expected to reach USD 2.8 billion by end of 2032.

 

  • Cancer remains a leading cause of morbidity and mortality worldwide, with many patients facing limited treatment options, especially in late stage of the disease. Therefore, cell therapies offer a promising avenue for addressing this unmet medical need by providing innovative and potentially curative treatment options.

     

  • Moreover, rapid advancement in immunotherapy including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors, have revolutionized cancer treatment by harnessing the body's immune system to target and eliminate cancer cells. This development of cell-based immunotherapies has propelled the usage of clinical trial services, thereby supplementing the growth of oncology-focused cell therapy clinical trials.

     

Based on end-use, the cell therapy clinical trial services market is classified into pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end-users. The pharmaceutical & biotechnology companies’ segment is expected to exhibit 10.9% CAGR between 2024 - 2032.

 

  • Pharmaceutical and biotechnology companies are investing heavily in research and development (R&D) efforts focused on cell therapies. The growing understanding of cellular biology, advancements in cell culture techniques, and innovative technologies such as gene editing have fueled interest in cell-based treatments. This increased investment drives the demand for clinical trial services to support the development and testing of cell therapies.

     

  • Moreover, pharmaceutical and biotechnology companies are actively developing novel cell therapies to address unmet medical needs and capitalize on market opportunities. As the pipeline grows, the demand for clinical trial services, including clinical trial management, regulatory affairs support, and specialized laboratory services, increases accordingly, thereby fostering the market size.

 

North America Cell Therapy Clinical Trial Services Market, 2021 – 2032 (USD Million)

In 2023, North America secured a substantial market share of 43.2% in the global cell therapy clinical trial services market and is expected to dominate throughout the forecast period.

 

  • The presence of robust biopharmaceutical industry with numerous pharmaceutical and biotechnology companies actively engaged in cell therapy research and development activities in North America coupled with substantial investment in innovative technologies and therapies, drives the demand for cell therapy clinical trial services in this region.

     

  • Moreover, regulatory agencies in North America, such as the Food and Drug Administration (FDA) in the U.S. and Health Canada, have established regulatory pathways and guidelines to facilitate the development and approval of cell therapies. Initiatives such as the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and expedited review programs accelerate the regulatory approval process for promising cell therapy products, thereby fostering growth in the market.

     

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.

 

  • Germany hosts leading academic and research institutions with expertise in cell biology, immunology, and regenerative medicine. Collaborations between industry sponsors and these institutions facilitate the design and conduct of innovative cell therapy clinical trials. Therefore, access to leading researchers, specialized facilities, and patient populations contributes to the growth of the market in Germany.

     

The Asia Pacific cell therapy clinical trial services market is expected to grow with a significant CAGR during the forecast period.

 

  • The region's abundant patient base, notably in nations such as China, India, South Korea, and Japan, presents significant market prospects. Furthermore, partnerships between industry stakeholders and governmental efforts serve to bolster growth in this vibrant and evolving market.

     

  • Moreover, the gradual migration of clinical trials from Western nations to Asian countries, driven by cost considerations and patient recruitment advantages, will further fuel growth in the regional market.

     

  • Further, the Asia-Pacific region is posed for substantial expansion within the cell and gene therapy market, propelled by factors such as escalating healthcare spending, a growing incidence of genetic disorders, and favorable regulatory environments.
Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
What is the size of cell therapy clinical trial services industry?
The cell therapy clinical trial services market was valued at USD 2.6 billion in 2023 and will grow at 10.6% CAGR during 2024-2032, driven by the growing prevalence of chronic diseases, such as cancer, and cardiovascular diseases.
How big is the North America cell therapy clinical trial services industry?
Why is the demand for cell therapy clinical trial regulatory affairs & compliance services growing?
Mention the key players involved in cell therapy clinical trial services industry?
Cell Therapy Clinical Trial Services Market Scope

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Rising incidence of chronic and genetic diseases

3.2.1.2    Technological advancement in cell therapy

3.2.1.3    Increasing investment in research & development activities

3.2.2    Industry pitfalls & challenges

3.2.2.1    Regulatory challenges

3.2.2.2    Complexity of cell therapy development

3.3    Growth potential analysis

3.4    Regulatory landscape

3.5    Porter’s analysis

3.6    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company matrix analysis

4.3    Competitive analysis of major market players

4.4    Competitive positioning matrix

4.5    Strategic dashboard

Chapter 5   Market Estimates and Forecast, By Service, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Clinical trial design & planning

5.3    Supply & logistics services

5.4    Regulatory affairs & compliance

5.5    Data management & biostatistics

5.6    Site management & monitoring

5.7    Other services

Chapter 6   Market Estimates and Forecast, By Phase, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Phase I

6.3    Phase II

6.4    Phase III

6.5    Phase IV

Chapter 7   Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    Oncology

7.3    Hematology

7.4    Neurology

7.5    Cardiovascular diseases

7.6    Musculoskeletal disorders

7.7    Other indications

Chapter 8   Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)

8.1    Key trends

8.2    Pharmaceutical & biotechnology companies

8.3    Contract research organizations

8.4    Academic & research institutes

8.5    Other end-users

Chapter 9   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

9.1    Key trends

9.2    North America

9.2.1    U.S.

9.2.2    Canada

9.3    Europe

9.3.1    Germany

9.3.2    UK

9.3.3    France

9.3.4    Spain

9.3.5    Italy

9.3.6    Netherlands

9.3.7    Rest of Europe

9.4    Asia Pacific

9.4.1    Japan

9.4.2    China

9.4.3    India

9.4.4    Australia

9.4.5    South Korea

9.4.6    Rest of Asia Pacific

9.5    Latin America

9.5.1    Brazil

9.5.2    Mexico

9.5.3    Rest of Latin America

9.6    Middle East and Africa

9.6.1    South Africa

9.6.2    Saudi Arabia

9.6.3    UAE

9.6.4    Rest of Middle East and Africa

Chapter 10   Company Profiles

10.1    ICON PLC

10.2    IQVIA

10.3    Medpace, Inc.

10.4    Laboratory Corporation of America Holdings

10.5    Parexel International

10.6    Worldwide Clinical Trials

10.7    Charles River Laboratories International, Inc.

10.8    Syneos Health

10.9    Thermo Fisher Scientific Inc.

10.10    Novotech

10.11    Catalent Pharma

10.12    Precision Medicine Group, LLC

Authors: Mariam Faizullabhoy, Gauri Wani
Buy Now
$4,123 $4,850
15% off
$4,280 $5,350
20% off
$5,845 $8,350
30% off
    Buy now
Premium Report Details

Base Year: 2023

Companies covered: 12

Tables & Figures: 282

Countries covered: 22

Pages: 172

Download Free Sample

Top